Mebias Funding

National Institute on Drug Abuse (NIDA)

According to the NIH HEAL Initiative (https://heal.nih.gov), “More than 47,000 Americans died of opioid overdose in 2017, and more than 2 million Americans live with addiction to opioids. Moreover, more than 50 million Americans suffer from chronic pain, and of those, 25 million live with daily chronic pain and lack effective and safe non-opioid options for pain management.

In 2018, NIDA awarded a five-year UG3/UH3 grant to Mebias Discovery, Inc. in support of a drug abuse and addiction research project entitled, “Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorder.” 

In 2025, NIDA awarded another two-year UG3 grant (of a 5-year UG3/UH3 grant program) to Mebias Discovery, Inc. in support of a drug abuse and addiction research project entitled, “MEB-1170: A New Chemical Entity for the Treatment of Opioid Use Disorder.” 

BIOADVANCE

BioAdvance works closely with entrepreneurs to build strong companies in the mid-Atlantic region which are focused on improving human health. BioAdvance is a $50 million early stage life sciences fund, working with entrepreneurs in the mid-Atlantic region to build strong companies that have the potential to improve human health. Since making its first investments in 2003, BioAdvance has committed $35.7 million in funding to 80 organizations developing over 75 products in the diagnostics, therapeutic, medtech, research tools and digital health sectors. BioAdvance portfolio companies have leveraged $2.65 billion in subsequent capital, including proceeds from twelve acquisitions. Eleven products have received FDA approval.

Life Science Angels

Life Science Angels is a not-for-profit corporation with 130-150 accredited investor members, 12-18 highly qualified fellows, and 12-15 sponsor organizations. Our mission is to improve healthcare worldwide by helping entrepreneurs with disruptive advances in healthcare discovery and delivery.